If you've been following the research conversation around CST over the past several years, you may have noticed a shift. Earlier reviews — particularly the 2019 meta-analysis by Jäkel and von Hauenschild — reached broadly positive conclusions about CST's effects on pain and function. More recent reviews, published in 2024, are less encouraging. Some have read this as the evidence base moving against CST. The reality is more nuanced.
Understanding what changed between these reviews — not just in conclusions but in methodology, study pools, and design — gives a more accurate picture than any single headline can. The evidence on CST is still developing. What's happened over the past five years reflects the normal messiness of a field being studied, not a settled verdict.
What the 2019 meta-analysis found
The Jäkel and von Hauenschild meta-analysis, published in 2019, synthesised ten randomised controlled trials with 681 patients. It found significant effects of CST on pain and function, with effects lasting up to six months. This was a reasonable study pool for the CST literature at the time, and the six-month follow-up finding was particularly notable — sustained effects are more clinically meaningful than immediate post-treatment improvements that fade quickly.
The review was widely cited and became a reference point in discussions of CST evidence. It covered conditions including neck pain, fibromyalgia, and chronic pelvic pain, and the pooled analysis found consistent signals across them. For practitioners and patients looking for a summary of the research, it gave a useful snapshot of what the available trials showed.
The authors also acknowledged the limitations common to the field: relatively small individual trials, concerns about blinding quality, and the need for larger replication studies. The caveats were noted, but the headline finding was positive, and it provided reasonable grounds for cautious optimism about CST's potential for pain-related conditions.
What changed by 2024
Two notable reviews in 2024 drew on a larger body of studies and reached more sceptical conclusions. The Ceballos-Laita review included 15 RCTs. The Amendolara review covered 24 RCTs. Both applied updated quality assessment criteria and broader inclusion criteria than the 2019 analysis.
A few things changed between the reviews that help explain the shift. First, the pool of studies grew. New trials were conducted in the intervening years, some studying conditions where CST showed less clear benefit. Including a wider range of conditions and outcomes means that the aggregate picture is shaped by more variable results. Second, quality assessment tools have evolved, and tighter criteria tend to reduce confidence in the overall effect estimates from smaller or less rigorously designed trials. Third, a broader review will naturally include trials studying conditions where CST simply didn't perform as well as in conditions that had attracted earlier research attention.
None of this means the positive signals from the 2019 meta-analysis were wrong. It means that when you look across a larger set of conditions and apply more demanding standards, the consistent positive effect seen in a smaller, more selective pool of studies becomes harder to detect.
What the trajectory actually means
The shift from positive to more cautious in the review literature is not the same as evidence accumulating against CST. It's evidence accumulating — in a way that produces a more complicated picture than earlier, smaller analyses suggested. This is normal in research. Fields often go through a phase where early, somewhat selective evidence looks more promising than a broader evidence base ultimately supports.
Importantly, the condition-specific positive findings from well-designed trials don't disappear because a broader review is more sceptical. The 2015 neck pain RCT, the fibromyalgia trials, the infant colic study — those individual results still say what they said. They need to be held alongside the broader context, but they aren't cancelled by it.
For people who have experienced benefit from CST, or are considering it for a specific condition, the most useful approach is to look at the condition-specific evidence rather than treating 'CST works' or 'CST doesn't work' as a binary question. Some conditions have more encouraging trial data than others. The research is still evolving. The honest position is neither uncritical acceptance of all positive claims nor broad dismissal of a therapy that many people find helpful.
The movement from earlier positive reviews to more cautious recent ones reflects an evolving evidence base, not a settled conclusion. Reading the research carefully — what was studied, how conditions were selected, what the condition-specific results actually show — produces a more accurate picture than either the optimistic or the sceptical headline.